April 13, 2017

Innocrin Names New CEO and Gets Fast-tracked by FDA for Breast Cancer Treatment Seviteronel

News

Innocrin Pharmaceuticals has named Fred Eshelman, PharmD, as its new CEO and learned it was granted a second fast track designation for seviteronel (VT-464) for the treatment of several types of ... Read more

May 27, 2016May 27, 2016

Innocrin Pharmaceuticals Initiates Phase 2 Study of Seviteronel in Women with Difficult-to-Treat Breast Cancer

News

Innocrin Pharmaceuticals has initiated dosing in a Phase 2 clinical trial in patients with estrogen receptor-positive (ER+) or triple negative breast cancer (TN BCa) to determine the safety, tolerability, pharmacokinetics and activity ... Read more